CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
鞘内注射氢化可的松治疗儿童和年轻成人 CAR-T 细胞免疫效应细胞相关神经毒性综合征
英文原题：Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
查看英文原题
Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫效应细胞相关神经毒性综合征（ICANS）是嵌合抗原受体（CAR）T细胞治疗的重要毒性，首选治疗包括支持治疗和全身性糖皮质激素。关于进行性或难治性ICANS的处理，目前数据有限。本文报告5例复发/难治性B细胞急性淋巴细胞白血病（ALL）儿童及年轻成人患者；尽管接受全身激素治疗，其ICANS仍逐渐恶化，鞘内注射氢化可的松后迅速逆转。儿科ALL初始治疗中常规采用治疗性腰椎穿刺，且安全性已有证据支持，因此，值得进一步开展前瞻性研究，评估鞘内氢化可的松用于重度ICANS患者的疗效。
展开英文摘要原文
Immune-effector cell-associated neurotoxicity syndrome (ICANS) is a significant toxicity occurring with chimeric antigen receptor (CAR) T-cell therapy, with first-line treatment options including supportive care and systemic corticosteroids. Sparse data exist on how to approach progressive/refractory cases of ICANS.
We present five pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who had progressively worsening ICANS despite systemic steroids, and received intrathecal hydrocortisone with rapid reversal of ICANS. Therapeutic lumbar punctures are routinely used in upfront ALL therapy in pediatrics, with a demonstrable safety profile, thus use of intrathecal hydrocortisone merits further prospective studies in patients with severe ICANS.
论文信息
- 作者
- Shalabi H、Harrison C、Yates B、Calvo KR、Lee DW、Shah NN
- 单位
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.United States
- 期刊
- Pediatric blood & cancer2024 Jan
- 原文标识
- PubMed 37897136 · DOI 10.1002/pbc.30741
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →